Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 8, 2011, Pages 1906-1915

  Neoh, Chin Fen ^a   Liew, Danny ^b   Slavin, Monica ^c   Marriott, Debbie ^d   Chen, Sharon C A ^e   Morrissey, Orla ^a   Stewart, Kay ^a   Kong, David C M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

Antifungals; Candida spp.; Modelling

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CONVENTIONAL AMPHOTERICIN B; FLUCONAZOLE; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTICLE; AUSTRALIA; CLINICAL DECISION MAKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; ECONOMIC EVALUATION; HOSPITAL; HOSPITALIZATION; HUMAN; INVASIVE CANDIDIASIS; LIFE EXPECTANCY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL EXPERT; MONTE CARLO METHOD; MORTALITY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIFUNGAL AGENTS; AUSTRALIA; CANDIDIASIS, INVASIVE; COST-BENEFIT ANALYSIS; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79960441878     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr186     Document Type: Article

References (36)

1. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Thursky KA, Playford EG, Seymour JF et al. Recommendations for the treatment of established fungal infections. Intern Med J 2008; 38: 496-520.
3. Slavin M, Fastenau J, Sukarom I et al. Burden of hospitalisation of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis 2004; 8: 111-20.
4. Slavin MA. Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting. Intern Med J 2008; 38: 457-67.
5. Golan Y, Harrison D, Fahrbach K. An echinocandin vs. a comparator antifungal in Candida bloodstream infections: a meta-analysis. In: Abstracts of the Twentieth European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2010. Abstract O410. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
6. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
7. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16.
8. Cornely OA, Sidhu M, Odeyemi I et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008; 24: 1743-53.
9. Sidhu MK, van Engen AK, Kleintjens J et al. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the United Kingdom. Curr Med Res Opin 2009; 25: 2049-59.
10. Marriott DJ, Playford EG, Chen S et al. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13: R115.
11. Australian Bureau of Statistics. National Health Survey: Summary of Results (2005). http://www.ausstats.abs.gov.au/ausstats/subscriber.nsf/0/3B1917236618A042CA25711F00185526/$File/43640_2004-05. pdf (1 August 2010, date last accessed).
12. Australian Government of Health and Ageing. National Hospital Cost Data Collection. Round 13 (2008-09) Cost Report Version 5.2. http://www.health.gov.au/internet/main/publishing.nsf/Content/EB1A34EB4E8208ECCA25773B00031A09/$File/HeaderR13CWNatEst.pdf (1 August 2010, date last accessed).
13. Australian Bureau of Statistics. Consumer Price Index (2010). http://www.ausstats.abs.gov.au/ausstats/meisubs.nsf/0/DB27E14A103FB951CA25776D001B5ADF/$File/64010_jun%202010.pdf (1 August 2010, date last accessed).
14. Rechner IJ, Lipman J. The costs of caring for patients in a tertiary referral Australian intensive care unit. Anaesth Intensive Care 2005; 33: 477-82.
15. Australian Government of Health and Ageing. Medicare Benefits Schedule Book (2010). http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/BBE433BF3FE34A39CA257735001236D4/$File/201007-MBS.pdf (1 August 2010, date last accessed).
16. Health Purchasing Victoria. Health Purchasing Victoria Tender (2010-2012). http://www.hpv.org.au/ (3 November 2010, date last accessed).
17. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York: Oxford University Press, 2000.
18. Stam WB, Aversa F, Kumar RN et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungaltreatment in patients with neutropenic fever in Italy. Value Health 2008; 11: 830-41.
19. Bruynesteyn K, Gant V, McKenzie C et al. A cost-effectiveness analysis of caspofungin versus liposomal amphotericin B for treatment of suspected fungal infections in the United Kingdom. Eur J Haematol 2007; 78: 532-9.
20. Talmor D, Greenberg D, Howell MD et al. The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 2008; 36: 1168-74.
21. Angus DC, Linde-Zwirble WT, Clermont G et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31: 1-11.
22. Australian Bureau of Statistics. Australian Life Tables (2006-2008). http://www.abs.gov.au/ausstats/abs@.nsf/mf/3302.0.55.001/ (1 August 2010, date last accessed).
23. Quartin AA, Schein RM, Kett DH et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997; 277: 1058-63.
24. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). PharmacoEconomics 2001; 19: 1103-9.
25. O'Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. Health Econ 2007; 16: 1009-23.
26. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8.
27. Rotstein C, Cragin L, Laverdiere M et al. Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults. Can J Infect Dis Med Microbiol 2008; 19: 219-26.
28. Vandijck DM, Blot SI, Decruyenaere JM. Comment: Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother 2007; 41: 1916-7; author reply 1917.
29. Dixon S, McKeen E, Tabberer M et al. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. PharmacoEconomics 2004; 22: 421-33.
30. Johnson MD, Kleinberg M, Danziger L et al. Pharmacoeconomics of antifungal pharmacotherapy: challenges and future directions. Expert Opin Pharmacother 2005; 6: 2617-32.
31. Playford EG, Marriott D, Nguyen Q et al. Candidaemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034-9.
32. Davis SL, Vazquez JA, McKinnon PS. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidaemia in nonneutropenic patients. Ann Pharmacother 2007; 41: 568-73.
33. Gold M, Siegel J, Russell L et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
34. Al-Badriyeh D, Liew D, Stewart K et al. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J Antimicrob Chemother 2009; 63: 1276-85.
35. Al-Badriyeh D, Liew D, Stewart K et al. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. J Antimicrob Chemother 2009; 63: 197-208.
36. Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005; 55: 352-61.